Connecting Innovation to Purpose

15 Phase 1 dose escalation study (China): ASCO-GU 2024 KEY ELIGIBILITY Age >18 years Advanced urothelial carcinoma or Nectin-4 positive Advanced solid tumors ECOG 0-1 Adequate organ function. No uncontrolled diabetes No active CNS metastasis ESCALATION DESIGN Bayesian Optimal Interval [BOIN] design with accelerated titration at DL-1 IV Q3W over a 21-day cycle 0.2 mg/kg 0.6 mg/kg 1.2 mg/kg 1.8 mg/kg 2.7 mg/kg 3.6 mg/kg 4.5mg/kg (recruiting) KEY END POINTS Safety/tolerability Pharmacokinetics Anti tumor activity NEXT STEPS Continue escalation PK expansion at 3.6mg/kg MTD or RP2D Specific expansion

View entire presentation